Suzhou Ribo Licenses siRNA Delivery System from Life Techologies
publication date: Jun 19, 2013
Suzhou Ribo Life Sciences and Life Technologies of California have stuck a deal giving Ribo exclusive China rights to develop and manufacture siRNA therapeutics using Life's Invivofectamine® Rx delivery technology. Life Technologies will receive milestones and royalties for each drug that Ribo develops. Ribo’s first product is a treatment for hepatitis B. Invivofectamine® was originally produced as a research tool for knocking out genes in small-animal research models. Invivofectamine® Rx is based around a new class of lipid molecules that is 100-fold more powerful than the research product, while being less toxic, according to Life. More details....
Stock Symbol: (NSDQ: LIFE)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.